Iwona Kurkowska-Jastrzebska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/743440/publications.pdf

Version: 2024-02-01

67 papers

2,159 citations

20 h-index 233421 45 g-index

67 all docs

67
docs citations

67 times ranked 3065 citing authors

#	Article	IF	Citations
1	Liver transplantation as a treatment for Wilson's disease with neurological presentation: a systematic literature review. Acta Neurologica Belgica, 2022, 122, 505-518.	1.1	8
2	Involvement of progranulin (PGRN) in the pathogenesis and prognosis of breast cancer. Cytokine, 2022, 151, 155803.	3.2	4
3	Diagnostic Performance of Circulating miRNAs and Extracellular Vesicles in Acute Ischemic Stroke. International Journal of Molecular Sciences, 2022, 23, 4530.	4.1	8
4	Regulatory delays in a multinational clinical stroke trial. European Stroke Journal, 2021, 6, 120-127.	5.5	4
5	Kinetics of serum brain-derived neurotrophic factor (BDNF) concentration levels in epileptic patients after generalized tonic-clonic seizures. Epilepsy Research, 2021, 173, 106612.	1.6	9
6	Autonomic nervous system dysfunction in Wilson's disease – A systematic literature review. Autonomic Neuroscience: Basic and Clinical, 2021, 236, 102890.	2.8	2
7	Is there heart disease in cases of neurodegeneration associated with mutations in C19orf12?. Parkinsonism and Related Disorders, 2020, 80, 15-18.	2.2	3
8	Transcranial Magnetic Stimulation–Induced Motor Evoked Potentials in Hirayama Disease: Systematic Review of the Literature. Journal of Clinical Neurophysiology, 2020, 37, 181-190.	1.7	1
9	Semiquantitative Scale for Assessing Brain MRI Abnormalities in Wilson Disease: A Validation Study. Movement Disorders, 2020, 35, 994-1001.	3.9	43
10	Systematic and Multidisciplinary Evaluation of Fibromuscular Dysplasia Patients Reveals High Prevalence of Previously Undetected Fibromuscular Dysplasia Lesions and Affects Clinical Decisions. Hypertension, 2020, 75, 1102-1109.	2.7	20
11	Transcranial sonography changes in heterozygotic carriers of the ATP7B gene. Neurological Sciences, 2020, 41, 2605-2612.	1.9	3
12	Cerebrovascular reactivity and disease activity in relapsing-remitting multiple sclerosis. Advances in Clinical and Experimental Medicine, 2020, 29, 183-188.	1.4	9
13	Transcranial sonography changes in patients with Wilson's Disease during de-coppering therapy. Neurologia I Neurochirurgia Polska, 2020, 54, 185-192.	1.2	0
14	Pitfalls in diagnosing Wilson's Disease by genetic testing alone: the case of a 47-year-old woman with two pathogenic variants of the ATP7B gene. Neurologia I Neurochirurgia Polska, 2020, 54, 478-480.	1.2	8
15	Real-world effectiveness of fingolimod in Polish group of patients with relapsing-remitting multiple sclerosis. Clinical Neurology and Neurosurgery, 2019, 184, 105453.	1.4	3
16	Comparison of plasma, saliva, and hair lamotrigine concentrations. Clinical Biochemistry, 2019, 74, 24-30.	1.9	11
17	Brain volume is related to neurological impairment and to copper overload in Wilson's disease. Neurological Sciences, 2019, 40, 2089-2095.	1.9	27
18	Are antimigraine drugs that influence CGRP levels justified?. Pharmacological Reports, 2019, 71, 624-635.	3.3	1

#	Article	IF	CITATIONS
19	High incidence and clinical characteristics of fibromuscular dysplasia in patients with spontaneous cervical artery dissection: The ARCADIA-POL study. Vascular Medicine, 2019, 24, 112-119.	1.5	23
20	Increased burden of rare deleterious variants of the KCNQ1 gene in patients with large‑vessel ischemic stroke. Molecular Medicine Reports, 2019, 19, 3263-3272.	2.4	3
21	Stroke and TIA mimics in patients referred to a neurological emergency department by non-ambulance physicians, ambulance physicians and paramedics Neurologia I Neurochirurgia Polska, 2019, 53, 83-89.	1.2	6
22	Embolic strokes of undetermined source in a cohort of Polish stroke patients. Neurological Sciences, 2018, 39, 1041-1047.	1.9	13
23	Transcranial Sonography in Mitochondrial Membrane Protein-Associated Neurodegeneration. Clinical Neuroradiology, 2018, 28, 385-392.	1.9	5
24	Noninfectious complications of acute stroke and their impact on hospital mortality in patients admitted to a stroke unit in Warsaw from 1995 to 2015. Neurologia I Neurochirurgia Polska, 2018, 52, 168-173.	1.2	4
25	Measurement of Nutritional Status Using Body Mass Index, Waist-to-Hip Ratio, and Waist Circumference to Predict Treatment Outcome in Females and Males with Acute First-Ever Ischemic Stroke. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 132-139.	1.6	16
26	Cytokines in the pathogenesis of hemophilic arthropathy. Cytokine and Growth Factor Reviews, 2018, 39, 71-91.	7.2	30
27	MicroRNAs as Diagnostic and Prognostic Biomarkers in Ischemic Stroke—A Comprehensive Review and Bioinformatic Analysis. Cells, 2018, 7, 249.	4.1	131
28	PRECIOUS: PREvention of Complications to Improve OUtcome in elderly patients with acute Stroke. Rationale and design of a randomised, open, phase III, clinical trial with blinded outcome assessment. European Stroke Journal, 2018, 3, 291-298.	5 . 5	19
29	Infections Diagnosed after Admission to a Stroke Unit and Their Impact on Hospital Mortality in Poland from 1995 to 2015. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 1775-1782.	1.6	2
30	Mechanisms of cardioembolic stroke revisited. Atrial cardiopathy. Kardiologia Polska, 2018, 76, 314-319.	0.6	2
31	Analysis of the Role of CX3CL1 (Fractalkine) and Its Receptor CX3CR1 in Traumatic Brain and Spinal Cord Injury: Insight into Recent Advances in Actions of Neurochemokine Agents. Molecular Neurobiology, 2017, 54, 2167-2188.	4.0	80
32	Comparison of Plasma, Saliva, and Hair Levetiracetam Concentrations. Therapeutic Drug Monitoring, 2017, 39, 263-268.	2.0	11
33	Valproic acid malabsorption in 30 year-old female patient – Case study. Neurologia I Neurochirurgia Polska, 2017, 51, 259-262.	1.2	0
34	Evolution and novel radiological changes of neurodegeneration associated with mutations in C19orf12. Parkinsonism and Related Disorders, 2017, 39, 71-76.	2.2	22
35	Mechanical thrombectomy in acute stroke – Five years of experience in Poland. Neurologia I Neurochirurgia Polska, 2017, 51, 339-346.	1.2	11
36	Serum metalloproteinase 9 levels increase after generalized tonic-clonic seizures. Epilepsy Research, 2017, 129, 33-36.	1.6	22

#	Article	IF	CITATIONS
37	Intracerebral hemorrhage in the context of cerebral amyloid angiopathy and varied time of onset of cerebral venous thrombosis: a case report. Folia Neuropathologica, 2017, 3, 242-248.	1.2	4
38	Population-Specific Associations of Deleterious Rare Variants in Coding Region of P2RY1–P2RY12 Purinergic Receptor Genes in Large-Vessel Ischemic Stroke Patients. International Journal of Molecular Sciences, 2017, 18, 2678.	4.1	10
39	The phosphodiesterase inhibitor, ibudilast, attenuates neuroinflammation in the MPTP model of Parkinson's disease. PLoS ONE, 2017, 12, e0182019.	2.5	43
40	Non-paraneoplastic variant of limbic encephalitis – case report. Postepy Psychiatrii I Neurologii, 2017, 26, 255-269.	0.2	О
41	Changes in pre-hospital management of vascular risk factors among patients admitted due to recurrent stroke in Poland from 1995 to 2013. Archives of Medical Science, 2016, 4, 754-759.	0.9	5
42	Carotid intima media thickness and blood biomarkers of atherosclerosis in patients after stroke or myocardial infarction. Croatian Medical Journal, 2016, 57, 548-557.	0.7	16
43	Matrix Metalloproteinase 9 in Epilepsy: The Role of Neuroinflammation in Seizure Development. Mediators of Inflammation, 2016, 2016, 1-14.	3.0	62
44	Novel mutation of the NOTCH3 gene in a Polish family with CADASIL. Neurologia I Neurochirurgia Polska, 2016, 50, 262-264.	1.2	7
45	Pharmacy switch of antipsychotic medications: patient's perspective. Annals of General Psychiatry, 2015, 14, 31.	2.7	3
46	Readiness Visual Analog Scale: A Simple Way to Predict Post-Stroke Smoking Behavior. International Journal of Environmental Research and Public Health, 2015, 12, 9536-9541.	2.6	2
47	WÅ,osy jako matryca biologiczna. Czy badanie stä™Å½enia ksenobiotyków we wÅ,osach to przeszÅ,oÅ>ć, czy przyszÂ,oÅ>ć?. Postepy Psychiatrii I Neurologii, 2015, 24, 165-173.	0.2	O
48	The "smoker's paradox―in cardiovascular diseases: A review of the arguments for and against. Postepy Psychiatrii I Neurologii, 2015, 24, 18-25.	0.2	0
49	Eye of the tiger sign in a 23year patient with mitochondrial membrane protein associated neurodegeneration. Journal of the Neurological Sciences, 2015, 352, 110-111.	0.6	13
50	Blood–brain barrier markers after acute epileptic seizures. Journal of Neuroimmunology, 2014, 275, 28.	2.3	2
51	Neurodegeneration and inflammation in hippocampus in experimental autoimmune encephalomyelitis induced in rats by one – Time administration of encephalitogenic T cells. Neuroscience, 2013, 248, 690-698.	2.3	15
52	Potential neuroprotective effect of ibuprofen, insights from the mice model of Parkinson's disease. Pharmacological Reports, 2013, 65, 1227-1236.	3.3	39
53	Inflammation and gliosis in neurological diseases – clinical implications. Journal of Neuroimmunology, 2011, 231, 78-85.	2.3	78
54	Downâ€regulation of microglia and NG2â€positive cells reaction in trimethyltinâ€injured hippocampus of rats treated with myelin basic proteinâ€reactive T cells: Possible contribution to the neuroprotective effect of T cells. Journal of Neuroscience Research, 2010, 88, 24-32.	2.9	5

#	Article	IF	CITATIONS
55	Age- and sex-differences in the nitric oxide synthase expression and dopamine concentration in the murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Research, 2009, 1261, 7-19.	2.2	38
56	Anti-myelin basic protein T cells protect hippocampal neurons against trimethyltin-induced damage. NeuroReport, 2007, 18, 425-429.	1.2	9
57	Influence of Age and Gender on Cytokine Expression in a Murine Model of Parkinson's Disease. NeuroImmunoModulation, 2007, 14, 255-265.	1.8	26
58	Gender Differences in Neurological Disease: Role of Estrogens and Cytokines. Endocrine, 2006, 29, 243-256.	2.2	98
59	Ibuprofen and the mouse model of Parkinson's disease. Annals of Neurology, 2006, 59, 988-989.	5.3	14
60	Cyclooxygenases mRNA and protein expression in striata in the experimental mouse model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to mouse. Brain Research, 2004, 1019, 144-151.	2.2	41
61	Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. International Immunopharmacology, 2004, 4, 1307-1318.	3.8	106
62	Dynamics of expression of the mRNA for cytokines and inducible nitric synthase in a murine model of the Parkinson's disease. Acta Neurobiologiae Experimentalis, 2003, 63, 117-26.	0.7	33
63	Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide. Medical Science Monitor, 2002, 8, RA165-77.	1.1	69
64	Inflammatory changes in the substantia nigra and striatum following MPTP intoxication. Annals of Neurology, 2000, 48, 127-127.	5.3	13
65	The Inflammatory Reaction Following 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Intoxication in Mouse. Experimental Neurology, 1999, 156, 50-61.	4.1	338
66	Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology, 1998, 39, 167-180.	2.0	261
67	Microglial Reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) Induced Parkinson's Disease Mice Model. Experimental Neurology, 1996, 5, 137-143.	1.7	245